Quick Answer
Arbutus Biopharma Corp reported Total Assets of $94.62 million for the year ending 2025.
- Arbutus Biopharma Corp showed a decrease of -28.2% in Total Assets from 2024 to 2025.
- This data is from Arbutus Biopharma Corp's annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $138.52 million | Q2 2014: $132.07 million | Q3 2014: $125.06 million | Q1 2015: $787.06 million | Q2 2015: $773.82 million | Q3 2015: $722.63 million | Q1 2016: $703.25 million | Q2 2016: $530.86 million | Q3 2016: $514.73 million | Q1 2017: $268.14 million | Q2 2017: $255.08 million | Q3 2017: $239.85 million | Q1 2018: $270.03 million | Q2 2018: $277.01 million | Q3 2018: $245.42 million | Q1 2019: $209.22 million | Q2 2019: $192.57 million | Q3 2019: $117.28 million | Q1 2020: $102.61 million | Q2 2020: $97.63 million | Q3 2020: $131.10 million | Q1 2021: $146.24 million | Q2 2021: $135.38 million | Q3 2021: $165.60 million | Q1 2022: $236.88 million | Q2 2022: $215.84 million | Q3 2022: $203.80 million | Q1 2023: $191.22 million | Q2 2023: $176.82 million | Q3 2023: $158.64 million | Q1 2024: $150.29 million | Q2 2024: $160.04 million | Q3 2024: $140.44 million | Q1 2025: $117.01 million | Q2 2025: $103.27 million | Q3 2025: $97.71 million.
- Over the full 16 years of available data (2010 to 2025), Arbutus Biopharma Corp's Total Assets has grown by 350.1%.
- Historical annual values: Fiscal year 2025: $94.62 million | Fiscal year 2024: $131.71 million | Fiscal year 2023: $144.40 million | Fiscal year 2022: $195.42 million | Fiscal year 2021: $204.49 million | Fiscal year 2020: $137.08 million | Fiscal year 2019: $105.54 million | Fiscal year 2018: $227.91 million | Fiscal year 2017: $237.16 million | Fiscal year 2016: $275.92 million | Fiscal year 2015: $712.29 million | Fiscal year 2014: $118.18 million | Fiscal year 2013: $71.72 million | Fiscal year 2012: $52.60 million | Fiscal year 2011: $13.99 million | Fiscal year 2010: $21.02 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: